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Angiotensin II-Induced Effects on Adipose and Skeletal
Muscle Tissue Blood Flow and Lipolysis in Normal-
Weight and Obese Subjects
G. H. GOOSSENS, E. E. BLAAK, W. H. M. SARIS, AND M. A. VAN Baak
Department of Human Biology, Nutrition and Toxicology Research Institute Maastricht, Maastricht University, 6200 MD
Maastricht, The Netherlands
The present study was designed to investigate the effects of
angiotensin II (Ang II) on adipose and skeletal muscle tissue
blood flow and lipolysis in normal-weight and obese subjects
using the microdialysis technique. Microdialysis probes were
placed in the abdominal sc adipose tissue left and right from
the umbilicus and in the gastrocnemius muscle of both legs in
eight normal-weight and eight obese men. Probes were con-
secutively perfused with 1.0 nM Ang II, 1.0 M Ang II, and 1.0
M Ang II  48 M hydralazine or with Ringer solution (con-
trol). Ethanol and glycerol concentrations in the dialysate
were measured as an indicator of local blood flow and lipol-
ysis, respectively. Ang II caused an increase in ethanol out-
flow/inflow ratio, compared with baseline values both in ad-
ipose tissue (average of both groups, Ang 1.0 nM: 0.03  0.01,
P 0.02; Ang 1.0 M: 0.05 0.01, P < 0.01) and muscle (average
of both groups, Ang 1.0 nM: 0.02  0.01, P  0.09; Ang 1.0 M:
0.04 0.01, P 0.01), indicating a decrease in local blood flow.
These effects were not significantly different in obese and
normal-weight subjects. The decrease in local blood flow was
accompanied by unchanged interstitial glycerol concentra-
tions in adipose tissue (except during the supraphysiological
dose) and skeletal muscle, suggesting that Ang II inhibits li-
polysis in both tissues. Thus, the present data suggest that Ang
II decreases local blood flow in a dose-dependent manner and
inhibits lipolysis both in adipose and skeletal muscle tissue.
These effects were not significantly different in obese and
normal-weight subjects in both tissues. (J Clin Endocrinol
Metab 89: 2690–2696, 2004)
THE OCTAPEPTIDE ANGIOTENSIN II (Ang II) is theactive component of the renin-angiotensin system
(RAS). In addition to Ang II synthesis in the circulation,
several components of the RAS, like angiotensinogen, renin,
and angiotensin-converting enzyme, have been identified in
a variety of tissues (1, 2), implying that these tissues have the
ability to synthesize Ang II independently of circulating RAS
components. There is accumulating evidence to suggest that
a local RAS is present both in adipose and skeletal muscle
tissue. However, the physiological role of Ang II in these
tissues remains to be established. There is evidence that the
RAS in adipose tissue may affect adipocyte growth and dif-
ferentiation, adipose tissue blood flow, and lipolysis and
may be involved in the pathophysiology of obesity and
obesity-related disorders, as has been reviewed recently (3).
Findings on the effects of Ang II on tissue blood flow and
lipolysis are controversial. Boschmann et al. have shown that
Ang II decreased blood flow and inhibited lipolysis in adi-
pose tissue of normal-weight men (4) and women (5). How-
ever, they could not confirm these findings in subsequent
studies, in which they showed that Ang II had no effect on
adipose tissue blood flow and it stimulated rather than in-
hibited lipolysis in this tissue in normal-weight men (6). In
another study in nonobese and obese subjects, Ang II had no
effect on adipose and skeletal muscle tissue blood flow in
both groups and exerted a lipolytic effect in adipose tissue
and an antilipolytic effect in skeletal muscle tissue in nono-
bese, but not in obese men (7). Finally, it has been demon-
strated that iv infusion of Ang II reduces forearm blood flow,
and locally produced Ang II seemed to be more important for
vasoconstriction in the forearm than Ang II delivered via the
circulation (8).
Thus, the effects of Ang II on blood flow and lipolysis in
adipose and skeletal muscle tissue are not yet fully under-
stood and need to be studied in further detail. In addition,
with regard to the possible involvement of Ang II in the
pathophysiology of obesity, it is of particular interest to find
out whether Ang II exerts different effects on tissue blood
flow and lipolysis in normal-weight and obese subjects be-
cause it has been shown before that adipose tissue blood flow
and lipolysis are disturbed in obese individuals during cat-
echolamine stimulation (9, 10). Therefore, the aim of this
study was to examine the effects of Ang II on adipose and
skeletal muscle tissue blood flow and lipolysis in the fasting




Eight normal-weight (body mass index 25 kg/m2) and eight obese
(body mass index  30 kg/m2) male subjects participated in this study.
Physical characteristics of the subjects are summarized in Table 1. Body
density was determined by underwater weighing after an overnight fast.
Lung volume was measured simultaneously with the helium dilution
technique using a spirometer (Volugraph 2000, Mijnhardt, Bunnik, The
Netherlands). Body weight was measured with a digital balance, accu-
rate to 0.001 kg (type E1200; August Sauter GmbH, Albstadt, Germany).
Abbreviations: Ang II, Angiotensin II; ANP, atrial natriuretic peptide;
RAS, renin-angiotensin system.
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Body fat percentage was calculated using the equation of Siri (11). All
subjects were in good health as assessed by medical history and spent
no more than 2 h/wk in organized sports activities. The Medical-Ethical
Committee of Maastricht University approved the study protocol, and
all subjects gave their written informed consent before participating in
the study.
Protocol
All subjects were asked to refrain from drinking alcohol, smoking,
and doing strenuous exercise for a period of 24 h before the study.
Subjects came to the laboratory by car or bus in the morning after an
overnight fast. On arrival, four microdialysis catheters (CMA 60, CMA
Microdialysis AB, Stockholm, Sweden) were inserted before the start of
the experiment. Microdialysis probes were placed in the abdominal sc
adipose tissue under sterile conditions 6–8 cm left and right from the
umbilicus. One hour before insertion of these probes, the skin was
anesthetized by means of a cream containing lidocaine (25 mg/g) and
prilocaine (25 mg/g) (EMLA, AstraZeneca BV, Zoetermeer, The Neth-
erlands). Furthermore, microdialysis probes were inserted in the medial
portion of the gastrocnemius muscle of both legs after anesthesia (xy-
locaine 2% without adrenalin, AstraZeneca). Thereafter, 90 min was
allowed for recovery of the skeletal muscle and adipose tissue from the
insertion trauma.
The probes (30  0.6 mm2, molecular weight cut-off of 20 000) con-
sisted of a dialysis tubing glued to the end of a double-lumen polyure-
thane cannula. The perfusion solvent enters the probe through the inner
cannula, passes down to the tip of the probe, streams upward in the
space between the inner cannula and the outer dialysis membrane and
leaves the probe through the outer cannula via a side arm from which
it is collected in a capped microvial.
After insertion, all probes were perfused with Ringer solution (147
mm sodium, 4 mm potassium, 2.25 mm calcium, and 156 mm chloride,
Baxter BV, Utrecht, The Netherlands), supplemented with 50 mm eth-
anol, at a flow rate of 0.5 l/min (Harvard microinfusion pump, Plato
BV, Diemen, The Netherlands). After 90 min recovery, the real interstitial
glycerol concentration was determined individually by means of the
zero flow method (12, 13) (see Zero flow method). Microdialysate was
collected in two 20-min fractions at a flow rate of 0.5 l/min and in three
10-min fractions at flow rates of 1.0, 2.5, and 5.0 l/min. The calibration
period with a flow rate of 5.0 l/min was used as baseline measurement
for the second part of the experiment.
During the second part of the experiment, the experimental probes in
adipose and skeletal muscle tissue were consecutively perfused with 1.0
nm Ang II (Ang 1.0 nm), 1.0 m Ang II (Ang 1.0 m), and 1.0 m Ang
II 48 m hydralazine (Ang 1.0 mH), each dose for 60 min at a flow
rate of 5.0 l/min, to examine the effect of Ang II on local blood flow
and lipolysis (ethanol and glycerol concentrations in the dialysate, re-
spectively). The highest perfusion dose of Ang II was also administered
in combination with the vasodilatator hydralazine to counteract the
possible Ang II-induced vasoconstriction and, therefore, to distinguish
between the possible direct and blood flow-mediated effects of Ang II
on the interstitial glycerol concentration. The other probes in adipose
and skeletal muscle tissue served as control probes and were perfused
with Ringer solution (50 mm ethanol) at a similar perfusion rate during
the whole experiment. There was a wash-out period of 30 min perfusion
with Ringer solution (50 mm ethanol) between each perfusion step
(Fig. 1).
Microdialysate was collected in fractions corresponding to 10 min
during the second part of the experiment. In all samples collected at flow
rates of 0.5, 1.0, and 2.5 l/min, dialysate glycerol concentration was
measured. Both dialysate glycerol and ethanol concentrations were de-
termined in all other samples. Furthermore, ethanol concentration was
determined both in the ingoing and outgoing perfusion solvent to assess
the ethanol outflow/inflow (out/in) ratio as indicator for local nutritive
blood flow (ethanol dilution technique) (14, 15). The interstitial glycerol
concentration was used to assess changes in lipolysis. Ethanol concen-
trations were determined the same day, whereas the samples for mea-
surement of the interstitial glycerol concentration were immediately
frozen in liquid nitrogen and stored at80 C until analysis. All changes
in ethanol out/in ratios and glycerol concentrations observed in the
different experimental conditions were adjusted for corresponding
changes in the control probes to take into account changes over time in
tissue blood flow and lipolysis that were not due to the intervention.
These adjustments were made by subtracting changes in the experi-
mental probes by changes in the control probes. Adjusted values are
presented as changes from baseline values because of the interindividual
variations in baseline concentrations.
Zero flow method
During the first part of the experiment, the real interstitial glycerol
concentration was determined by means of the zero flow method (12,
13). Therefore, the microdialysis probes were perfused with Ringer
solution at a flow rate of 0.5 l/min for 40 min and at consecutive flow
rates of 1.0, 2.5, and 5.0 l/min for 30 min. Dialysate glycerol concen-
trations were log transformed and plotted against perfusion rates. Linear
regression analysis was used to calculate the glycerol concentration at
zero flow rate, corresponding to the real interstitial glycerol concentra-
tion. The ratio between the dialysate glycerol concentration at 5.0l/min
and the calculated interstitial glycerol concentration represents the in
vivo recovery of the probe, and all dialysate glycerol samples collected
during the second part of the experiment were adjusted for the in vivo
recovery of the corresponding probe.
Analyses
Glycerol and ethanol concentrations were determined on a Cobas
Fara centrifugal analyzer (Roche Diagnostica, Basel, Switzerland). Glyc-
erol concentration was measured fluorometrically using a standard glyc-
erol kit (Boehringer, Mannheim, Germany), but with adjusted concen-
trations of NADH, enzymes and buffer, to achieve accurate fluorometric
detection. Ethanol concentration was measured spectrophotometrically
TABLE 1. Physical characteristics of subjects
Characteristic Normal weight(n  8)
Obese
(n  8)
Age (yr) 52  2 49  3
Weight (kg) 76.6  2.1a 112.8  6.4
Height (m) 1.78  0.03 1.78  0.02
BMI (kg/m2) 24.3  0.5a 35.5  1.8
Body fat (%) 22.8  1.5b 34.6  2.7
Values are means  SEM. Unpaired t test.
a P  0.001.
b P  0.01.
FIG. 1. Experimental design.
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at a wavelength of 340 nm using a standard ethanol kit (176290,
Boehringer).
Statistical analysis
Data are presented as mean  sem. To compare the effects of the
different perfusion solvents within and between groups, a repeated-
measures ANOVA was performed. Post hoc testing was performed using
the Student’s paired or unpaired t tests. Calculations were done using
Statview 5.0 for iMac (SAS Institute, Cary, NC). P 0.05 was considered
to be statistically significant.
Results
By definition, obese men had a significantly higher body
weight, body mass index, and body fat percentage, com-
pared with normal-weight men. Age and height of both
groups were similar (Table 1).
Ethanol out/in ratio
At baseline, ethanol out/in ratios were not significantly
different in obese subjects, compared with normal-weight
subjects, both in adipose tissue [average of experimental and
control probe: 0.84  0.07 (obese) vs. 0.79  0.10 (normal-
weight), P  0.17] and muscle [average of experimental and
control probe: 0.51  0.08 (obese) vs. 0.46  0.06 (normal-
weight), P  0.10] (Fig. 2, A and B). As expected, baseline
ethanol out/in ratios were higher in adipose tissue than in
skeletal muscle in both groups, reflecting a lower blood flow
in abdominal sc adipose tissue, compared with skeletal
muscle.
During perfusion with Ang II, there was a significant
dose-dependent increase in ethanol out/in ratios, com-
pared with baseline values both in adipose tissue (average
of both groups, Ang 1.0 nm: 0.03  0.01, P  0.02; Ang 1.0
m: 0.05  0.01, P  0.01) and muscle (average of both
groups, Ang 1.0 nm: 0.02  0.01, P  0.09; Ang 1.0 m:
0.04  0.01, P  0.01) (Fig. 2, C and D), indicating a
decrease in local nutritive blood flow in both tissues. At
the lowest (physiological) dose of Ang II, the increase in
ethanol out/in ratios from baseline was 0.04  0.01 (P 
FIG. 2. Effects of Ang II on the ethanol out/in ratio in abdominal sc adipose tissue (A) and skeletal muscle (B) in eight normal-weight and eight
obese subjects. Data are adjusted for corresponding changes in the control probes and presented as changes from baseline values in adipose
tissue (C) and skeletal muscle (D). Values are means  SEM. *, P  0.05 vs. baseline; **, P  0.01 vs. baseline; #, P  0.05 vs. Ang 1.0 M; ##,
P  0.001 vs. Ang 1.0 M.
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0.01) and 0.02 0.02 (NS) in adipose tissue and 0.03 0.01
(P  0.08) and 0.01  0.01 (NS) in skeletal muscle in obese
and normal-weight subjects, respectively. However, the
differences in increase from baseline between groups did
not reach statistical significance. When expressed as per-
centage increase in ethanol out/in ratio, similar results
were obtained (data not shown).
In adipose as well as skeletal muscle tissue, perfusion with
1.0 m Ang II  48 m hydralazine (Ang 1.0 m  H)
significantly lowered ethanol out/in ratios, compared with
perfusion with the highest dose of Ang II alone (average of
both groups: 0.05  0.02, P  0.01 vs. 0.12  0.01, P 
0.001, respectively), indicating an increase in local blood
flow. Compared with baseline values, perfusion with Ang 1.0
m  H decreased ethanol out/in ratios in muscle (average
of both groups: 0.08  0.01, P  0.001) but did not signif-
icantly change ethanol out/in ratios in adipose tissue of both
groups.
Interstitial glycerol concentration
Baseline interstitial glycerol concentrations in adipose tis-
sue were not significantly different in obese compared with
normal weight subjects (average of experimental and control
probe: 197  108 (obese) vs. 148  65 m (normal-weight),
P 0.14) (Fig. 3A). Interstitial glycerol concentration in skel-
etal muscle of obese subjects was significantly higher than
that of normal-weight subjects under baseline conditions
(average of experimental and control probe: 103 28 (obese)
vs. 84  19 m (normal-weight), P  0.04) (Fig. 3B). As
expected, baseline interstitial glycerol concentrations were
higher in adipose tissue than in skeletal muscle in both
groups. In adipose tissue, the only significant change in
interstitial glycerol concentration from baseline was found
during perfusion with Ang 1.0 m (average of both groups:
51.3  20.2 m, P  0.02) (Fig. 3C). This increase from base-
line was 42.1 30.9m (NS) in obese and 59.4 28.2m (P
FIG. 3. Effects of Ang II on the interstitial glycerol concentration in abdominal sc adipose tissue (A) and skeletal muscle (B) in eight normal-
weight and eight obese subjects. Data are adjusted for corresponding changes in the control probes and presented as changes from baseline
values in adipose tissue (C) and skeletal muscle (D). Values are means  SEM. *, P  0.05 vs. baseline; #, P  0.05 vs. Ang 1.0 M.
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0.07) in normal-weight subjects. However, the differences in
increase from baseline between groups did not reach statis-
tical significance. In skeletal muscle, the only significant
change in interstitial glycerol concentration from baseline
was observed during perfusion with Ang 1.0 m  H (av-
erage of both groups: 19.1 8.8m, P 0.05) (Fig. 3D). When
expressed as percentage increase in interstitial glycerol con-
centration, similar results were obtained (data not shown).
Discussion
It is tempting to postulate that in addition to Ang II pro-
duced in the circulation, locally produced Ang II may affect
local nutritive blood flow and lipolysis in adipose and skel-
etal muscle tissue, and may thereby affect fat accumulation
in these tissues. However, the physiological significance of
Ang II in these processes remains to be established.
Local blood flow and lipolysis
The present data show that Ang II stimulation in situ
causes an increase in ethanol out/in ratios both in adipose
and skeletal muscle tissue, indicating a decrease in local
blood flow. This finding is in agreement with the well-known
vasoconstrictive effect of Ang II in the systemic circulation
and its role in elevating blood pressure (16). The decrease in
blood flow in both tissues was not significantly different in
obese and normal-weight subjects. Inhibition of local blood
flow will retain glycerol in the tissue (17), thereby increasing
the interstitial glycerol concentration due to product accu-
mulation. However, the Ang II-induced reduction in blood
flow was accompanied by interstitial glycerol concentrations
that were not different from baseline values in adipose tissue
and skeletal muscle during stimulation with the lower dose
of Ang II (1.0 nm), suggesting that Ang II inhibits lipolysis in
both tissues. The elevation in glycerol concentration in the
dialysate observed when adipose tissue was stimulated with
the highest (supraphysiological) dose of Ang II, despite an
Ang II-induced inhibition of lipolysis, might be explained by
the extra vasoconstriction that occurred. However, we can-
not exclude that Ang II stimulation in situ may cause a
dose-dependent biphasic response, with an antilipolytic ef-
fect of Ang II at the physiological concentration, and no effect
or a lipolytic effect at supraphysiological concentrations.
The normal concentration of Ang II in plasma is about 10
pm (18). However, it should be mentioned that local Ang II
production might result in higher Ang II concentrations in
the interstitial space than in the circulation. For example, Ang
II concentration in the interstitial space of the rat kidney has
been shown to be about 30-fold higher than the circulating
Ang II concentration (19). In addition, with the present per-
fusion rate only a small fraction (probably less than 20%) of
Ang II in the perfusate will diffuse into the interstitial space.
Therefore, the lowest dose of Ang II used in the present study
(1.0 nm) most likely corresponds to an interstitial Ang II
concentration that is within the physiological range.
In line with our findings, others have found that Ang II
reduces blood flow and inhibits lipolysis in adipose tissue of
normal-weight men (4) and women (5). However, they could
not confirm these findings in subsequent studies, in which
they showed that Ang II had no effect on adipose and skeletal
muscle tissue blood flow, and it stimulated rather than in-
hibited lipolysis in adipose tissue, whereas it inhibited li-
polysis in muscle in normal-weight men (6). In a recent study,
Ang II had no effect on adipose and skeletal muscle tissue
blood flow in nonobese and obese subjects and exerted a
lipolytic effect in adipose tissue and an antilipolytic effect in
skeletal muscle in nonobese but not in obese men (7). In
contrary to the above-mentioned studies, control probes
were used in the present study to take into account changes
over time in tissue blood flow and lipolysis that were not due
to the intervention. Additionally, the nonobese and obese
subjects in the present study were well matched for age,
which was not the case in the study of Boschmann et al. (7).
Furthermore, a wash-out period of 30-min perfusion with
Ringer solution between each perfusion step was included in
our design to prevent that Ang II applied in a previous
perfusion step would affect the following condition.
During perfusion with the highest dose of Ang II in com-
bination with the vasodilating agent hydralazine (Ang 1.0
m  H) in muscle, local blood flow was tremendously
increased, and the interstitial glycerol concentration was sig-
nificantly elevated, compared with the highest dose of Ang
II alone, indicating that hydralazine itself exerts a strong
lipolytic effect in skeletal muscle. During perfusion with Ang
1.0 m  H in adipose tissue, blood flow and interstitial
glycerol concentration were not significantly different from
baseline. Because of the antilipolytic effect of Ang II in ad-
ipose tissue, this suggests that hydralazine also stimulates
lipolysis in adipose tissue, although this effect is less clear
than in skeletal muscle. Indeed, there is some indirect evi-
dence that strengthens our observations. In vascular smooth
muscle cells, the main action of hydralazine is to inhibit the
inositol 1,4,5-triphosphate-induced release of Ca2 from the
sarcoplasmic reticulum (20). Interestingly, increasing intra-
cellular Ca2 inhibits lipolysis in a dose-dependent manner
in rat adipocytes (21). In line with this, the agouti gene prod-
uct inhibits lipolysis in human adipocytes via an increase in
intracellular Ca2 (22). Thus, low concentrations of intracel-
lular Ca2 may stimulate lipolysis. Therefore, hydralazine
may lead to an increased rate of lipolysis by inhibiting the
inositol 1,4,5-triphosphate-induced release of Ca2 into the
cytosol in vivo.
Underlying mechanisms for the antilipolytic effect
Although less is known about the physiological effects of
Ang II on adipose and skeletal muscle tissue lipolysis, there
are mechanisms that may explain the antilipolytic effect of
Ang II found in the present study. There is evidence that Ang
II may act on the sympathetic nervous system. Under resting
conditions, lipolysis is primarily regulated (inhibited) by the
activity of 2-adrenergic receptors (23, 24), and it has been
demonstrated that Ang II augments the release of noradren-
aline from brown adipose tissue sympathetic nerve terminals
(25). Thus, the antilipolytic effects of Ang II observed in the
present study may be due to stimulation or potentiation of
2-adrenergic activity. In addition, it has been demonstrated
that binding of Ang II to the angiotensin type 1 receptor
inhibits adenylate cyclase in smooth muscle cells, the kidney,
and hepatocytes (26, 27). Therefore, Ang II might inhibit
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adenylate cyclase in adipose and skeletal muscle tissue as
well, which in turn may cause an inhibition of lipolysis (28).
In this respect, a novel pathway controlling human adipose
tissue lipolysis has been discovered recently. It was demon-
strated that atrial natriuretic peptide (ANP) exerted a lipo-
lytic effect via a cGMP-dependent pathway in human adi-
pocytes (29). Interestingly, Ang II has been shown to
counteract the ANP-stimulated cGMP synthesis in cultured
podocytes (30) and glomerular mesangial cells (31). There-
fore, it may be that Ang II inhibits lipolysis in adipose and
skeletal muscle tissue by inhibiting the ANP-stimulated
cGMP synthesis. Furthermore, Ang II has been shown to
increase the intracellular Ca2 concentration in pancreatic
(32) and vascular smooth muscle cells (33). Taking into ac-
count the finding that increasing intracellular Ca2 inhibited
lipolysis (21, 22), it may be that the Ang II-induced antili-
polytic effect in adipose and skeletal muscle tissue observed
in the present study was caused by an increase in the intra-
cellular Ca2 concentration in these tissues.
Role of Ang II in obesity
The Ang II-induced effects on adipose and skeletal muscle
tissue blood flow and lipolysis are not significantly different
in obese and normal-weight subjects. However, the tendency
toward a small difference in tissue blood flow and lipolysis
between groups warrants further research to substantiate
these results. Because there is evidence for the existence of a
local RAS in adipose tissue (3), it is tempting to speculate that
a higher Ang II formation in adipose tissue of obese subjects
may contribute to fat accumulation in adipose and skeletal
muscle tissue in these individuals. Interestingly, fat accu-
mulation in skeletal muscle is negatively associated with
insulin sensitivity in obese and type 2 diabetic subjects (34,
35). However, further studies are necessary because even if
Ang II production in adipose tissue is elevated in obese
subjects, it may be that higher Ang II concentrations lead to
down-regulation of Ang II responsiveness. Furthermore,
Ang II may be, at least in part, responsible for the reported
lower basal adipose tissue blood flow in obese compared
with lean subjects (9, 36–38) and may explain the signifi-
cantly increased basal adipose tissue blood flow observed
after weight reduction (9).
Conclusion
The present data suggest that Ang II stimulation in situ
decreases local blood flow in a dose-dependent manner and
inhibits lipolysis in both adipose and skeletal muscle tissue.
These effects were not significantly different in obese and
normal-weight subjects both in tissues. Furthermore, our
data suggest that the vasodilatator hydralazine exerts a li-
polytic effect in skeletal muscle and adipose tissue, although
this effect is less clear in the latter tissue.
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